Allergy Immunotherapy Market – Overview
This report studies the current as well as future prospects of the global allergy immunotherapy market. Stakeholders of the market include companies and intermediaries engaged in the manufacture, commercialization, and provision of immunotherapeutic drugs for treatment of allergy, as well as new players planning to enter the market. The report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. The section also provides overall information and data analysis of the global allergy immunotherapy market with respect to the leading market segments based on treatment type, allergy type, distribution channel, and region.
The global allergy immunotherapy market has been segmented based on treatment type, allergy type, distribution channel, and region. In terms of treatment type, the market has been classified into subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). Based on allergy type, the global allergy immunotherapy market has been categorized into allergic rhinitis, asthma, food allergy, venom allergy, and others. In terms of distribution channel, the market has been divided into hospital pharmacies, retail pharmacies & drug stores, and online pharmacies.
Each of the market segments has been extensively analyzed based on market-related factors such as increase in incidence and prevalence of allergy. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.
The market overview section of the report explores the market dynamics such as drivers, restraints, opportunities, and pipeline drugs that currently have a strong impact on the allergy immunotherapy market and are likely to influence the market in the near future. Market attractiveness analysis has been provided in the overview section in order to explain the intensity of competition in the market across different regions. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors are expected to help market players take strategic decisions to strengthen their positions and enhance their shares in the global allergy immunotherapy market.
Geographically, the global allergy immunotherapy market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The report provides market size and forecast for the major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market and opportunities has been provided in the overview section. It also provides market attractiveness analysis and market share analysis of key players, thereby presenting a thorough examination of the overall competitive scenario of the global allergy immunotherapy market.
Major players operating in the global allergy immunotherapy market are Stallergenes Greer, Aimmune Therapeutics, ALK-Abello A/S, Allergy Therapeutics, Merck KGaA (Allergopharma), HAL Allergy Group, DBV Technologies, Circassia, Biomay AG, and Anergis.
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2 Assumptions and Research Methodology
Chapter 3 Executive Summary: Global Allergy Immunotherapy Market
Chapter 4 Market Overview
4.1. Introduction
4.2. Key Industry Developments
Chapter 5 Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Global Allergy Immunotherapy Market Size (US$ Mn) Forecast, 2015-2025
5.5. Global Allergy Immunotherapy Market Outlook
Chapter 6 Global Allergy Immunotherapy Market Analysis and Forecast, by Treatment Type
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Treatment Type, 2017-2025
6.3.1. Subcutaneous Immunotherapy (SCIT)
6.3.2. Sublingual Immunotherapy(SLIT)
6.4. Market Attractiveness Analysis, by Treatment Type
Chapter 7 Global Allergy Immunotherapy Market Analysis and Forecast, by Allergy Type
7.1. Key Findings
7.2. Market Size (US$ Mn) Forecast, by Allergy Type, 2017-2025
7.2.1. Allergic Rhinitis
7.2.2. Asthma
7.2.3. Food Allergy
7.2.4. Venom Allergy
7.2.5. Others
7.3. Market Attractiveness Analysis, by Allergy Type
7.4. Key Trends
Chapter 8 Global Allergy Immunotherapy Market Analysis and Forecast, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy and Drug Stores
8.3.3. Online Pharmacy
8.4. Market Attractiveness Analysis, by Distribution Channel
Chapter 9 Global Allergy Immunotherapy Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Market Value (US$ Mn) Forecast, by Region, 2017-2025
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Market Attractiveness Analysis, by Region
Chapter 10 North America Allergy Immunotherapy Market Analysis and Forecast
10.1. Key Findings
10.2. Market Size (US$ Mn) Forecast, by Country, 2017-2025
10.2.1. U.S.
10.2.2. Canada
10.3. Market Size (US$ Mn) Forecast, by Treatment Type, 2017-2025
10.3.1. SCIT
10.3.2. SLIT
10.4. Market Size (US$ Mn) Forecast, by Allergy Type, 2017-2025
10.4.1. Allergic Rhinitis
10.4.2. Asthma
10.4.3. Food Allergy
10.4.4. Venom Allergy
10.4.5. Other
10.5. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
10.5.1. Hospital Pharmacy
10.5.2. Retail Pharmacy and Drug Stores
10.5.3. Online Pharmacy
10.6. Market Attractiveness Analysis
10.6.1. By Country
10.6.2. By Treatment Type
10.6.3. By Allergy Type
10.6.4. By Distribution Channel
Chapter 11 Europe Allergy Immunotherapy Market Analysis and Forecast
11.1. Key Findings
11.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
11.2.1. Germany
11.2.2. U.K.
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Market Size (US$ Mn) Forecast, by Treatment Type, 2017-2025
11.3.1. SCIT
11.3.2. SLIT
11.4. Market Size (US$ Mn) Forecast, by Allergy Type, 2017-2025
11.4.1. Allergic Rhinitis
11.4.2. Asthma
11.4.3. Food Allergy
11.4.4. Venom Allergy
11.4.5. Others
11.5. Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2025
11.5.1. Hospital Pharmacy
11.5.2. Retail Pharmacy and Drug Stores
11.5.3. Online Pharmacy
11.6. Market Attractiveness Analysis
11.6.1. By Country
11.6.2. By Treatment Type
11.6.3. By Allergy Type
11.6.4. By Distribution Channel
Chapter 12 Asia Pacific Allergy Immunotherapy Market Analysis and Forecast
12.1. Key Findings/Developments
12.2. Market Overview
12.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
12.3.1. China
12.3.2. India
12.3.3. Japan
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Market Size (US$ Mn) Forecast, by Treatment Type, 2017-2025
12.4.1. SCIT
12.4.2. SLIT
12.5. Market Size (US$ Mn) Forecast, by Allergy Type, 2017-2025
12.5.1. Allergic Rhinitis
12.5.2. Asthma
12.5.3. Food Allergy
12.5.4. Venom Allergy
12.5.5. Others
12.6. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
12.6.1. Hospital Pharmacy
12.6.2. Retail Pharmacy and Drug Stores
12.6.3. Online Pharmacy
12.7. Market Attractiveness Analysis
12.7.1. By Country
12.7.2. By Treatment Type
12.7.3. By Allergy Type
12.7.4. By Distribution Channel
Chapter 13 Latin America Allergy Immunotherapy Market Analysis and Forecast
13.1. Key Findings/Developments
13.2. Market Overview
13.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Market Size (US$ Mn) Forecast, by Treatment Type, 2017-2025
13.4.1. SCIT
13.4.2. SLIT
13.5. Market Size (US$ Mn) Forecast, by Allergy Type, 2017-2025
13.5.1. Allergic Rhinitis
13.5.2. Asthma
13.5.3. Food Allergy
13.5.4. Venom Allergy
13.5.5. Others
13.6. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
13.6.1. Hospital Pharmacy
13.6.2. Retail Pharmacy and Drug Stores
13.6.3. Online Pharmacy
13.7. Market Attractiveness Analysis
13.7.1. By Country/Sub-region
13.7.2. By Treatment Type
13.7.3. By Allergy Type
13.7.4. By Distribution Channel
Chapter 14 Middle East & Africa Allergy Immunotherapy Market Analysis and Forecast
14.1. Key Findings/Developments
14.2. Market Overview
14.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Israel
14.3.4. Rest of Middle East & Africa
14.4. Market Size (US$ Mn) Forecast, by Treatment Type, 2017-2025
14.4.1. SCIT
14.4.2. SLIT
14.5. Market Size (US$ Mn) Forecast, by Allergy Type, 2017-2025
14.5.1. Allergic Rhinitis
14.5.2. Asthma
14.5.3. Food Allergy
14.5.4. Venom Allergy
14.5.5. Others
14.6. Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2025
14.6.1. Hospital Pharmacy
14.6.2. Retail Pharmacy and Drug Stores
14.6.3. Online Pharmacy
14.7. Market Attractiveness Analysis
14.7.1. By Country/Sub-region
14.7.2. By Treatment Type
14.7.3. By Allergy Type
14.7.4. By Distribution Channel
Chapter 15 Pipeline Analysis
15.1.1. Allergy Immunotherapy Pipeline Analysis (2017)
Chapter 16 Allergy Immunotherapy - Regulatory Overview
16.1.1. Regulatory Status for European Union
16.1.2. Regulatory Status for U.S.
Chapter 17 Competition Landscape
17.1. Global Allergy Immunotherapy Market Share, by Company, 2017
17.2. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
17.2.1. ALK-Abello A/S
17.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.1.2. Product Portfolio
17.2.1.3. SWOT Analysis
17.2.1.4. Strategic Overview
17.2.2. Allergy Therapeutics
17.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.2.2. Product Portfolio
17.2.2.3. SWOT Analysis
17.2.2.4. Strategic Overview
17.2.3. Stallergenes Greer
17.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.3.2. Product Portfolio
17.2.3.3. SWOT Analysis
17.2.3.4. Financial Overview
17.2.3.5. Strategic Overview
17.2.4. HAL Allergy Group
17.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.4.2. Product Portfolio
17.2.4.3. SWOT Analysis
17.2.4.4. Financial Overview
17.2.4.5. Strategic Overview
17.2.5. DBV Technologies
17.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.5.2. Product Portfolio
17.2.5.3. SWOT Analysis
17.2.5.4. Financial Overview
17.2.5.5. Strategic Overview
17.2.6. Merck KGaA
17.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.6.2. Product Portfolio
17.2.6.3. SWOT Analysis
17.2.6.4. Financial Overview
17.2.6.5. Strategic Overview
17.2.7. Aimmune Therapeutics
17.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.7.2. Product Portfolio
17.2.7.3. SWOT Analysis
17.2.7.4. Financial Overview
17.2.7.5. Strategic Overview
17.2.8. Circassia
17.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.8.2. Product Portfolio
17.2.8.3. SWOT Analysis
17.2.8.4. Financial Overview
17.2.8.5. Strategic Overview
17.2.9. Anergis
17.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.9.2. Product Portfolio
17.2.9.3. SWOT Analysis
17.2.9.4. Financial Overview
17.2.9.5. Strategic Overview
17.2.10. Biomay AG
17.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.10.2. Product Portfolio
17.2.10.3. SWOT Analysis
17.2.10.4. Financial Overview
17.2.10.5. Strategic Overview
